HEMATOPOIETIC TRANSPLANTATION FOR AML

$0P01FY2002CANIH

University Of Texas Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 38856690 Paper 37725573 Paper 37038957 Paper 33438761 Paper 31127149 Paper 30674535 Paper 30337364 Paper 29655803 Paper 29490944 Paper 29463558 Paper 29435107 Paper 29232553 Paper 29137349 Paper 28659338 Paper 28388555 Paper 28270436 Paper 27391151 Paper 27268264 Paper 27129202 Paper 26956049 Paper 26838606 Paper 26822154 Paper 26752456 Paper 26704388 Paper 26674329 Paper 26431162 Paper 26340096 Paper 26183077 Paper 26095711 Paper 26045609 Paper 26031918 Paper 25867648 Paper 25598437 Paper 25558171 Paper 25530214 Paper 25406351 Paper 25223583 Paper 25079338 Paper 24858343 Paper 24766216 Paper 24739393 Paper 24737502 Paper 24727332 Paper 24628293 Paper 24619500 Paper 24619497 Paper 24599548 Paper 24596420 Paper 24526787 Paper 24510534 Paper 24346116 Paper 24337870 Paper 24170028 Paper 24154679 Paper 24144307 Paper 24092807 Paper 23841653 Paper 23838935 Paper 23691988 Paper 23676502 Paper 23669290 Paper 23611563 Paper 23565503 Paper 23564911 Paper 23530930 Paper 23397500 Paper 23345254 Paper 23333150 Paper 23266036 Paper 23260083 Paper 23247046 Paper 23036488 Paper 23005582 Paper 22893484 Paper 22892554 Paper 22826565 Paper 22826139 Paper 22796535 Paper 22785211 Paper 22687754 Paper 22645176 Paper 22585577 Paper 22498477 Paper 22490334 Paper 22368688 Paper 22363446 Paper 22249254 Paper 22136251 Paper 22100978 Paper 22064351 Paper 22033489 Paper 22023523 Paper 22005650 Paper 21988645 Paper 21986948 Paper 21949692 Paper 21904380 Paper 21868571 Paper 21853076 Paper 21767516

Abstract

The objectives of this project are to address the following questions and hypotheses related to hematopoietic transplantation for treatment of AML. During the previous grant period we developed a promising strategy. Using less-toxic, non-ablative preparative regimens for allogeneic transplantation, allowing engraftment and development of graft-vs.-leukemia responses and examined strategies to separate GVL from GVHD. We also established fludarabine as an effective immunosuppressive agent for hematopoietic transplantation and developed an intravenous form of bufsulfan for BMT applications. We also generated dendritic cells from leukemic precursors which stimulate autologous or allogeneic reactivity against AML. We extend these studies and will answer the following questions and hypotheses: 1) Can purine analog based non-ablative preparative regimens with allogeneic HSCT induce durable remissions in high-risk patients with AML as initial therapy or consolidation of initial remission? 2) What is optimal dose and schedule of busulfan and fludarabine in allogeneic HSCT in patients with recurrent AML? 3) Can leukemic dendritic cell primed autologous or allogeneic T-cells induce anti-leukemic responses in vivo? 4) Does resistance to apoptosis affect the response of AMP to adoptive immunotherapy.? This will be examined by studying induction of apoptosis in vitro in patients responding or not responding to these immunotherapeutic approaches. The ultimate goal of this project is to more efficiently induce graft-vs-leukemia as a primary therapy for AML.

View original record on NIH RePORTER →